AUPH
Aurinia Pharmaceuticals Inc.
AUPH's fundamentals are strong and it looks cheap: trading at 7.1x earnings, less than half its usual 26x. Analysts expect earnings to hold roughly steady.
AUPH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
AUPH's revenue, profitability, cash flow and balance sheet are all currently healthy.
AUPH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 7.1x | $16.18 | -0.2% |
| Current | 7.1x | $16.21 | — |
| Forward | 19x | $16.21 | — |
| Fair | 26x | $59.75 | +269% |
| Expensive | 31x | $70.12 | +333% |
Historical ranges are pointers, not guarantees.
AUPH's PE is in its cheap range at 7.1x. On analysts' estimates for next year's earnings, today's price would be 19x, in its fair range.
AUPH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Stable | |
| Growth | |
| Strongly weakening | |
| Limited | |
| Moderate |
Analysts expect AUPH's revenue to grow, but its profitability to weaken.
AUPH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.83 | -64% |
| Q3 2026 | $2.29 | +309% |
| Q2 2026 | $2.29 | +433% |
| Q1 2026 | $2.17 | +675% |
| Q4 2025 | $2.08 | +4060% |
| Q3 2025 | $0.56 | +$0.71 |
| Q2 2025 | $0.43 | +$0.77 |
| Q1 2025 | $0.28 | +$0.71 |
| Q4 2024 | $0.05 | +$0.59 |
AUPH's earnings per share have climbed steadily: $2.29 over the past year, about four times what it earned the year before, and higher year over year for 17 quarters in a row.
AUPH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $83.7M | +14% |
| Q2 2026 | $83.2M | +19% |
| Q1 2026 | $77.7M | +24% |
| Q4 2025 | $77.1M | +29% |
| Q3 2025 | $73.5M | +8.4% |
| Q2 2025 | $70M | +22% |
| Q1 2025 | $62.5M | +24% |
| Q4 2024 | $59.9M | +33% |
AUPH's revenue has grown year over year for 12 quarters in a row: $84M last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 42% | +1.8 points |
| Q2 2026 | 56% | +27 points |
| Q1 2026 | 53% | +18 points |
| Q4 2025 | 43% | +46 points |
| Q3 2025 | 40% | +23 points |
| Q2 2025 | 29% | +31 points |
| Q1 2025 | 35% | +61 points |
| Q4 2024 | -2.8% | +63 points |
AUPH's operating margin was 42% last quarter, up 1.8 points from the same quarter a year ago.
AUPH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $46.4M | +4.3% |
| Q2 2026 | $52.6M | +19% |
| Q1 2026 | $32.6M | +2405% |
| Q4 2025 | $45.7M | +52% |
| Q3 2025 | $44.4M | +161% |
| Q2 2025 | $44.2M | +179% |
| Q1 2025 | $1.3M | +$19.9M |
| Q4 2024 | $30.1M | +110% |
AUPH generated $177M in free cash flow over the past year, up 48% from the year before.
AUPH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +1.6M shares |
| 1 year | -0.6% | -835K shares |
| 3 years | -5.4% | -7.7M shares |
| 5 years | +5.2% | +6.7M shares |
| Available history | +38% | +37.2M shares |
AUPH has 135M diluted shares, down 0.6% from a year ago, with $75M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $38.7M |
| Q1 2026 | $36.2M |
| Q4 2025 | — |
| Q3 2025 | $8.7M |
| Q2 2025 | $42.6M |
| Q1 2025 | $46.9M |
| Q4 2024 | $21.8M |
AUPH spent $75M buying back its own shares over the past year, down 38% from the year before.
AUPH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.3x | Net Cash |
| Q2 2026 | -1.1x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | -0.6x | Net Cash |
| Q3 2025 | -1.0x | Net Cash |
| Q2 2025 | -1.0x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
AUPH has more cash than debt.
AUPH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.9 | Neutral |
| Stochastic | 57.0 | Neutral |
AUPH's weekly RSI is 52 (neutral) and its Stochastic is 57 (neutral).
AUPH PE vs Healthcare Sector
| Metric | AUPH | Sector median | Relative |
|---|---|---|---|
| PE | 7.1x | 26x | 73% below |
| PE % | 18 | 29 | 11 pts below |
AUPH is trading at 7.1x earnings, a 73% discount to the Healthcare sector's median of 26x.
AUPH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $16.5 | 1.5% below |
| 20 week MA | $16.1 | 0.5% above |
| 50 week MA | $15.6 | 3.9% above |
| 100 week MA | $12.7 | 27% above |
| 200 week MA | $10.3 | 57% above |
AUPH's trend is up, with a small recent dip: it's below only its 8-week average, and 57% above its 200-week average.
AUPH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $21.4 | $14.2 | -34% |
| 2021 | $14.2 | $23.1 | +63% |
| 2022 | $23.1 | $4.53 | -80% |
| 2023 | $4.53 | $8.99 | +98% |
| 2024 | $8.99 | $9.20 | +2.3% |
| 2025 | $9.20 | $16.3 | +77% |
| 2026 YTD | $16.3 | $16.2 | -0.2% |
AUPH has finished higher in four of the last six years, three of them by more than 50%. It's roughly flat so far in 2026.